| Autor: |
Paulus Kirchhof, Michael D. Ezekowitz, Yanish Purmah, Sonja Schiffer, Isabelle L. Meng, A. John Camm, Stefan H. Hohnloser, Anke Schulz, Melanie Wosnitza, Riccardo Cappato |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
TH Open, Vol 04, Iss 01, Pp e20-e32 (2020) |
| Druh dokumentu: |
article |
| ISSN: |
2512-9465 |
| DOI: |
10.1055/s-0040-1701206 |
| Popis: |
Introduction This X-VeRT (eXplore the efficacy and safety of once-daily oral riVaroxaban for the prevention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion) substudy evaluated the effects of treatment with rivaroxaban or a vitamin-K antagonist (VKA) on levels of biomarkers of coagulation (D-dimer, thrombin–antithrombin III complex [TAT] and prothrombin fragment [F1.2]) and inflammation (high sensitivity C-reactive protein [hs-CRP] and high-sensitivity interleukin-6 [hs-IL-6]) in patients with atrial fibrillation (AF) who were scheduled for cardioversion and had not received adequate anticoagulation at baseline (defined as, in the 21 days before randomization: no oral anticoagulant; international normalized ratio |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
